Director of Digital Medicine, Scripps Translational Science Institute
Cardiology
Dr. Steven R. Steinhubl, MD
|
|
Give Review
Dr. Steven R. Steinhubl works in the field of Cardiology. He graduated from Saint Louis University School of Medicine. Saint Louis University School of Medicine has a rank of 67 in research and a 57 in primary care He received awards:"CMS Meaningful Use Stage 1 Certification" and "Fellow (FACC)". Steven Steinhubl is a published doctor. He published 79 publications, including: 'Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism: The CVRN VTE Study.'
Publications
- Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism: The CVRN VTE Study.
- Digital medical tools and sensors.
- Automatic identification of Heart failure diagnostic criteria, using text analysis of clinical notes from electronic health records.
- Prevalence of Heart failure signs and symptoms in a large primary care population identified through the use of text and data mining of the electronic health record.
- Implementation of mobile health tools--reply.
- Improving cardiovascular outcomes using electronic health records.
- Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects.
- Antiplatelet therapy in prevention of cardio- and venous thromboembolic events.
- Can Mobile Health Technologies Transform Health Care?
- Impact of Proton Pump Inhibitor Therapy on the Efficacy of Clopidogrel in the CAPRIE and CREDO Trials.
- Ticagrelor : the first novel reversible P2Y(12) inhibitor.
- Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonism.
- Salivary biomarkers associated with Myocardial necrosis: results from an alcohol septal ablation model.
- Oral fluids that detect cardiovascular Disease biomarkers.
- Platelet-Mediated Thrombosis and Drug-Eluting Stents.
- Being successful at prevention: making it easy to do the right thing: comment on "improving care after Myocardial infarction using a 2-year internet-delivered interven...
- Historical Observations on the Discovery of Platelets, Platelet Function Testing and the First Antiplatelet Agent.
- Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with Acute coronary syndromes: results from the Acute Cathe...
- Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous Coronary intervention.
- Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window.
- Development and validation of a bleeding risk model for patients undergoing elective percutaneous Coronary intervention.
- Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines.
- Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist.
- The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis.
- Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high at...
- G-protein-coupled receptors as signaling targets for antiplatelet therapy.
- Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused ...
- Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous Coronary intervention: Insights from the Clopidogrel for the Reduction of Events D...
- Impact of clopidogrel in patients with Acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis.
- Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable Coronary artery disease.
- Why have antioxidants failed in clinical trials?
- Efficacy and safety of clopidogrel pretreatment before percutaneous Coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.
- Vulnerable plaque intervention: State of the art.
- Atrial fibrillation in the setting of Acute myocardial infarction--irregularly irregular treatment.
- Platelet activation and its patient-specific consequences.
- Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect.
- Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous Coronary intervention: quantitative review of randomized trials.
- Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation Acute coronary syndromes: results from the SYNERGY trial.
- Platelet function monitoring in patients with Coronary artery disease.
- Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils.
- Variation in the definitions of bleeding in clinical trials of patients with Acute coronary syndromes and undergoing percutaneous coronary interventions and its impact...
- Aspirin dose for the prevention of cardiovascular Disease: a systematic review.
- Oral antiplatelet therapy for percutaneous Coronary revascularization.
- Platelets as mediators of inflammation.
- Variable response to antiplatelet therapy: what does it mean to clinicians?
- Risk stratification for patients undergoing nonurgent percutaneous Coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reducti...
- Risk stratifying the Acute coronary syndrome patient: a focus on treatable risk.
- The evolving algorithm concerning higher-risk PCI (TEACH-PCI). Introduction.
- First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the c...
- The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous Coronary intervention trials.
- Early coronary revascularization diminishes the risk of ischemic stroke with Acute myocardial infarction.
- Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous Coronary revascularization.
- Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers.
- Clopidogrel-statin interaction: a mountain or a mole hill?
- Heparin-induced thrombocytopenia and cardiovascular Diseases.
- Clopidogrel treatment prior to percutaneous Coronary intervention: when enough isn't enough.
- Optimizing antiplatelet therapy for the ACS patient: reacting to clinical trial data from the ISAR-REACT-2 studies.
- Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study.
- Clopidogrel for percutaneous Coronary revascularization: time for more pretreatment, retreatment, or both?
- Resistance to antiplatelet resistance is it justified?
- Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials.
- The use of anti-inflammatory analgesics in the patient with cardiovascular Disease: what a pain.
- Variability in platelet responsiveness to clopidogrel among 544 individuals.
- Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study.
- Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous Coronary interv...
- Clopidogrel: how good is it and how does it work?
- Antiplatelet effect of aspirin in patients with cerebrovascular Disease.
- Safety and efficacy of aspirin, clopidogrel, and warfarin after Coronary stent placement in patients with an indication for anticoagulation.
- Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with Heart failure: the Plavix Us...
- Determination of the natural history of aspirin resistance among stable patients with cardiovascular Disease.
- Percutaneous Coronary interventions in patients with renal insufficiency: a high-risk, under-studied cohort.
- Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested.
- Antiplatelet therapy: aspirin.
- Usefulness of the response to sublingual nitroglycerin as a predictor of ischemic chest pain in the emergency department.
- Glycoprotein IIb/IIIa receptor inhibitor-thrombolytic combination therapy for Acute myocardial infarction.
- The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous Coronary intervention with abciximab the...
- Monitoring of platelet function in the setting of glycoprotein IIb/IIIa inhibitor therapy.
- Optimal Platelet Inhibition for PCI in ACS: Pretreatment, In-laboratory, Both or Neither.
Schools
Saint Louis University School Of Medicine
David Grant Med Center
Procedures Preformed
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac Myocardial Perfusion Imaging
- Cardioversion, Elective
- View All
Conditions Treated
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Valve Disease
- Arrhythmias (incl. Atrial Fibrillation)
- View All
Doctors Specialties
- Cardiology
- Interventional Cardiology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACC)
Education
-
Cleveland Clinic Foundation -
David Grant Medical Center -
Saint Louis University School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Gopi Dandamudi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jess W. Oren IV, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Henry F. Fesniak, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gouthami Boga, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John H. Chapman, MD |
|
|
Dr. Andrew C. Chough, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benny Johnson, MD |
|
|
Dr. Francis J. Menapace, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Louis A. Nassef Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Answer Qureshi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Luis E. Urrutia, MD |
|
|
Dr. William A. Schiavone, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Talwinderdeep S. Kahlon, MD |